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Purpose: To assess potential vascular, structural, and functional changes to the macula in 
patients with keratoconus that underwent ultraviolet A (UVA)–riboflavin-mediated corneal 
collagen cross-linking (CXL) therapy.
Patients and methods: Seventeen eyes from 17 patients of age 16 years or older with kerato-
conus undergoing CXL treatment were studied. The same eye served as its own control (before 
CXL vs after CXL). Eyes were evaluated in terms of best-corrected visual acuity (BCVA), 
refractive error, intraocular pressure, Amsler grid, retinography, fluorescein angiography, 
autofluorescence, and spectral domain optical coherence tomography (SD-OCT) prior to CXL 
and 7 and 30 days after treatment. Multifocal electroretinography (mfERG) was recorded prior 
to and 7 days after CXL.
Results: Mean (SD) BCVA by logMAR chart was 0.47 (±0.12) pre-CXL, 0.55 (±0.15) 7 days 
post-CXL (P=0.57), and 0.46 (±0.10) 30 days post-CXL (P=0.87). Mean (SD) SD-OCT central 
macular thickness (µm) was 253.62 (±20.9) pre-CXL, 260.5 (±18.7) 7 days post-CXL (P=0.48), 
and 256.44 (±21.6) 30 days post-CXL (P=0.69). In 12 eyes, mfERG revealed a statistically signifi-
cant increase (P=0.0353) in P1 latency (ms) of ring four from the pre-CXL period (39.45±2.05) 
to 7 days post-CXL (41.04±1.28) period. Regression analysis showed that the increase in P1 
latency was correlated with the increase in central macular thickness (P=0.027). Furthermore, nine 
patients experienced a significant decrease in P1 amplitudes of rings 1 (P=0.0014), 2 (P=0.0029), 
3 (P=0.0037), 4 (P=0.0014), and 5 (P=0.0012) from pre-CXL to 7 days post-CXL.
Conclusion: In this pilot study, most of the patients exhibited slight changes in their mfERG 
parameters and OCT thickness, despite a lack of vascular abnormalities observed on fluorescein 
angiography/autofluorescence imaging, no alteration in BCVA, and no reports of symptoms. 
These changes could, therefore, be categorized as a mild subclinical effect of the corneal cross-
linking procedure.
Keywords: keratoconus, light damage, multifocal electroretinogram, UVA, phototoxicity, 
crosslinking
Introduction
Keratoconus is a bilateral and noninflammatory corneal degenerative disorder distin-
guished by paracentral corneal thinning and secondary ectasia. It results in irregular 
astigmatism with impaired vision. The disease occurs in all racial groups, equally affects 
males and females, and is often asymmetrical. Onset is typically at puberty and is pro-
gressive until the third to fourth decade of life. The etiology is not fully understood, and 
several different biochemical, physical, and genetic pathways have been implicated. The 
condition itself is a common final pathway for several different diseases.1,2 The reported 
prevalence and incidence vary, but a recent study calculated an annual incidence of 1:7,500 
(13.3 cases per 100,000) and an estimated prevalence of 1:375 (265 cases per 100,000).3
Keratoconus management depends on the severity of the disease and the extent 
of irregular astigmatism. Eyeglasses, toric lenses, and rigid gas-permeable lenses are 
Correspondence: Paulo rodolfo Tagliari 
Barbisan
Department of Ophthalmology, state 
University of Campinas, rua Floriano 
Peixoto, 1853 – alto da Boa Vista, 
ribeirão Preto – sP, 14025-220, Brazil
Tel +55 169 9187 7107
Fax +55 163 911 1929
email paulortbarbisan@gmail.com 
Journal name: Clinical Ophthalmology
Article Designation: Original Research
Year: 2018
Volume: 12
Running head verso: Barbisan et al
Running head recto: Macular phototoxicity after corneal cross-linking
DOI: 176025
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
18
9.
22
8.
88
 o
n 
21
-N
ov
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology 2018:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1802
Barbisan et al
the treatment options for mild-to-moderate cases.2,4 Surgery 
(typically keratoplasty) becomes necessary when the disease 
progresses and in cases of contact lens intolerance, corneal 
scarring, and corneal thinning.2,5 However, none of these 
approaches treat the underlying causes of keratoconus or 
halt its progression.
Corneal collagen cross-linking (CXL) is a strengthen-
ing technology that alters the collagen matrix of the corneal 
stroma by creating riboflavin–ultraviolet A (UVA)-induced 
crosslinks.6,7 Riboflavin-catalyzed reactions generate free 
radicals that promote new collagen fibril bonds to a depth 
of ~200–300 µm and prevent further thinning of the corneal 
stroma by increasing the mechanical and biochemical rigidity 
and stability of stromal tissue.6–9 CXL has been found to be 
effective in the stabilization of moderate corneal ectasia, in 
decreasing maximum keratometry, and in improving best-
corrected visual acuity (BCVA).2,6,9,10 Numerous clinical 
studies have confirmed its efficacy in halting or aiding the 
regression of keratoconus.2,6,9,10
Phototoxic maculopathy is a retinal abnormality that 
generally affects patients after they engage in activities such 
as looking directly at a solar eclipse or welding without pro-
tection; it may also occur during accidents involving laser 
pointers or even after ocular surgery due to a photochemical 
reaction in light receptors. These patients may experience 
paracentral scotoma, metamorphopsia, or slight to moderate 
vision loss after exposure.11–13 The mechanisms by which 
light can cause damage to the retina are photothermal, pho-
tomechanical, and photochemical.14–16 Photothermal damage 
occurs through the transfer of radiant energy (a photon) from 
light to the retinal tissue, and common examples include 
transpupillary thermotherapy, laser photocoagulation, and 
micropulse diode laser. Photomechanical damage refers to 
tissue damage resulting from mechanical, compressive, or 
tensile forces generated by the rapid introduction of energy, 
such as that which is caused by the Nd:Yag laser. Photo-
chemical damage to the retina is independent of mechanical 
and thermal retinal damage, and this type of damage occurs 
after UV light exposure or the clinical use of photodynamic 
therapy.17 UVA is potentially more hazardous to the retina 
than other wavelengths.18,19 Its use during the CXL procedure 
raises concerns over potential damage to ocular structures 
and to the retina in particular.
Combined UVA–riboflavin treatment is known to cause 
endothelial toxicity in thin corneas (,400 µm) when the stan-
dard surface irradiation of 3 mW/cm is used.2,6,20,21 Although 
in vitro studies have found that the shielding effect of ribofla-
vin limits radiant transmission to inner ocular structures, few 
in vivo studies have been performed to assess morphological 
changes to the retina after UVA–riboflavin CXL, and there 
seem to be no studies in the literature that have analyzed 
functional damage to the retinal tissue.18,22,23
The objective of this study is to assess potential vascular, 
structural, and functional changes to the macula in patients 
with keratoconus after UVA–riboflavin CXL therapy.
Patients and methods
This study evaluated 17 eyes from 17 patients who were 
16 years of age or older, who had been diagnosed with kerato-
conus, and for whom treatment with corneal cross-linking had 
been indicated for at least one eye. All subjects were assessed 
in the Department of Ophthalmology of the Clinical Hospital 
of the State University of Campinas in Campinas, São Paulo 
State, Brazil. The same eye served as its own control (before 
CXL vs after CXL). Eyes were evaluated in terms of BCVA, 
refractive error, and intraocular pressure and using slit-lamp 
biomicroscopy, indirect ophthalmoscopy, the Amsler grid, 
color fundus imaging (retinography), fluorescein angiogra-
phy (FA), autofluorescence (AF), and spectral domain optical 
coherence tomography (SD-OCT) prior to CXL and 7 and 
30 days after the procedure. Multifocal electroretinography 
(mfERG) was recorded prior to and 7 days after CXL.
Patients were excluded if they were younger than 16 years 
of age, had any eye disease other than keratoconus, had 
a history of any ophthalmologic surgery in the eye being 
studied (including previous corneal cross-linking), were 
pregnant or breastfeeding, or exhibited any corneal opacity 
that would prevent clear vision of the retina or which would 
explain a loss of visual acuity. All participants provided 
informed written consent before participation; a parent 
or legal guardian signed the informed consent form when 
subjects were younger than 18 years of age. This study was 
approved by the Ethics Committee for Research on Human 
Subjects of the State University of Campinas and adhered 
to the Declaration of Helsinki.
Corneal cross-linking procedure
The UVA source was a solid-state device (X-Link Corneal 
Crosslinking System; Opto®, São Carlos, Brazil) consisting of 
a 9 mm UVA array with a potentiometric voltage regulator. 
Wavelength was 370 nm, and power was 3 mW/cm2 or 5.4 J/
cm2 when 1.5 cm from the cornea. After applying the blephar-
ostat, a marker (9 mm in diameter) was used to remove the 
corneal epithelium in a central circle with a blunt spatula. 
A photosensitizing solution (0.1% riboflavin – 400 MOSM; 
Ophthalmos®, São Paulo, Brazil) was applied every 3 minutes 
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over a 30-minute period. Riboflavin was applied every 
3 minutes during the 30 minutes of ultraviolet exposure. All 
of the surgeons who performed the procedure were at the 
same skill level. After treatment, patients were medicated 
four times per day with a topical antibiotic (moxifloxacin, 
Vigamox; Alcon®, São Paulo, Brazil) and the eye was dressed 
with a soft therapeutic contact lens for 5 days.
Optical coherence tomography
To evaluate the anatomy of the macular region of the retina, 
SD-OCT imaging was performed using a spectral domain 
device (Spectralis HRA®OCT; Heidelberg Engineering, 
Heidelberg, Germany). The pupil was dilated using 1% tropi-
camide and 10% phenylephrine drops. Patients were asked to 
gaze at the fixation light during the test, and foveal fixation 
was controlled by observing the retina through the infrared 
monitoring camera. Thickness of the macula region in 
the central ring was calculated using the retinal mapping 
software.
retinography, Fa, and aF
In order to perform retinal imaging and analyze the retinal 
vascular status of the macula and posterior pole of the retina, 
retinography and FA images were obtained using a fundus 
imaging device (Visucam® NM/FA; Carl Zeiss Meditec AG, 
Jena, Germany). The pupil was dilated using 1% tropicamide 
and 10% phenylephrine drops. AF images were obtained 
using the same device. Finally, a 10% solution of sodium 
fluorescein dye was administered intravenously as a bolus 
at a dose of 7.7 mg/kg and serial retinal photographs were 
taken for 15 minutes.
Multifocal electroretinography
Roland RETI-port/scan 21 system® (Roland Consult, Bran-
denburg a.d. Havel, Germany) was used to measure mfERG 
in accordance with the International Society for Clinical 
Electrophysiology of Vision. The pupil was dilated using 
1% tropicamide, and the cornea was anesthetized using 
0.5% tetracaine. The fellow eye was occluded by a pad. 
Subjects were asked to fixate on the central cross. Patients 
with low visual acuity were asked to fixate steadily on the 
center of the screen. HK-Loop electrodes were used as active 
electrodes to record mfERG signals. The neutral and refer-
ence electrodes were mounted on the frontal–central canthus 
and the external canthus, respectively. The recording process 
took ~10 minutes, during which time cross-fixation lines 
were displayed on the screen. The recording procedure was 
repeated if there were artifacts from eye blinks or if ocular 
movements were recorded. The stimulus, which consisted 
of 103 hexagons covering a visual field of 30°, was pre-
sented on a high-resolution color monitor (PC-System 21” 
monitor, mean luminance 180 cd/m2, high contrast). The 
eye-to-monitor distance was 33 cm, which corresponded to 
a stimulated field of ±30° horizontally and ±24° vertically. 
The central 30° of the retina was stimulated by flickering 
hexagons independently between black and white in a pseu-
dorandomized binary sequence. Hexagon size was scaled 
with eccentricity to evoke focal responses of approximately 
the same amplitude in the response arrays. Each record was 
collected in five segments and lasted 45 seconds. Every 
sequence lasted 16.6 ms and was followed by a rest interval 
of 66.4 ms before the next active sequence was initiated. 
According to the eccentricities, the amplitudes and latencies 
were evaluated in five-ring retinal regions. The first-order 
mfERG response components were analyzed. The mean 
response density of the P1 amplitude (amplitude per unit 
of retinal area [nV/deg2]) and the mean latency (ms) were 
determined. We selected the five most central hexagons to 
collect the central mfERG responses, which were averaged 
for the analysis. The mfERG examinations were performed 
before and 7 days after the CXL procedure.
statistical analysis
Data were analyzed using GraphPad Prism, version 7.0a. 
A descriptive statistical analysis was performed, and distri-
butions were summarized using proportions and means±SD. 
The D’Agostino–Pearson omnibus test was used to confirm 
the normality of the data. Patients’ data on clinical features 
were analyzed using the paired t-test. The paired t-test was 
also used on P1 amplitude data before and after CXL. P1 
latency was analyzed using the paired t-test and the pre- and 
post-CXL data. Correlation and regression analysis were 
also performed based on P1 latency. A significance level of 
P,0.05 was established for all of the analyses.
Results
Seventeen eyes from 17 subjects were included in the analysis. 
Mean (SD) age was 22.17 (±5) years (range 16–28 years). 
Sixty-three percent of the subjects were male. Mean (SD; 
Snellen) BCVA as per the logMAR chart was 0.47 (±0.12; 
20/59) pre-CXL, 0.55 (±0.15; 20/70) 7 days post-CXL, and 
0.46 (±0.10; 20/57) 30 days post-CXL, with no significant 
differences between pre-procedure data and the data obtained 
7 days after CXL (P=0.57) or 30 days after CXL (P=0.87). 
Mean (SD) near corrected visual acuity (Jaeger) was 2.42 
(±0.60) pre-CXL, 3.4 (±0.63) 7 days post-CXL, and 2.58 
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(±0.61) 30 days post-CXL, with no significant differences 
between pre-procedure data and the data obtained 7 days after 
CXL (P=0.19) or 30 days after CXL (P=0.80). Mean (SD) 
SD-OCT central macular thickness (µm) was 253.62 (±20.9) 
pre-CXL, 260.5 (±18.7) 7 days post-CXL, and 256.44 (±21.6) 
30 days post-CXL, with no significant differences between 
pre-procedure data and the data obtained 7 days after CXL 
(P=0.48) or 30 days after CXL (P=0.69; Tables 1 and 2). 
Subjects reported no changes on the Amsler grid test in the 
evaluations performed 7 and 30 days after CXL.
When the eyes were compared before and after CXL 
treatment, there were no changes in the fundus of the eye as 
determined using indirect ophthalmoscopy, biomicroscopy, 
or retinography, nor were there any abnormalities in the mac-
ular vascularity as determined using FA, or any changes to the 
retinal pigment epithelium based on AF imaging. Though the 
aforementioned changes in retinal thickness were observed, 
the intraretinal cysts, atrophy, outer retinal abnormalities, and 
other anatomical changes to the macular region typically seen 
in phototoxicity conditions16 were not observed via SD-OCT 
imaging when the eyes were compared before and after the 
CXL treatment. Intraocular pressure did not increase after 
the procedure or during the follow-up period.
In 12 eyes, mfERG revealed a statistically significant 
increase (P=0.0353) in P1 latency (ms) of ring 4 when pre-
CXL values (39.45±2.05) were compared to values obtained 
7 days post-CXL (41.04±1.28; Figure 1). Regression analysis 
in which P1 latency was a dependent variable of macular 
thickness showed that the increase in P1 latency in these sub-
jects (1.59±0.66) was correlated with the increase in central 
macular thickness in the SD-OCT scan (P=0.027; Figure 2; 
Table 3). Furthermore, nine patients were found to have a 
significant decrease in P1 amplitudes (nV/deg2) of rings 1–5 
when pre-CXL values were compared to the values 7 days 
Table 1 Demographic and clinical information on patients
Parameters Pre-CXL 7 days post-CXL P-value* 30 days post-CXL P-value*
age (years) 22.0±5.0 – – – –
gender (male, %) 63.64 – – – –
BCVa (logMar) 0.47±0.12 0.55±0.15 0.57 0.46±0.10 0.87
near visual acuity (Jaeger) 2.42±0.60 3.4±0.63 0.19 2.58±0.61 0.80
sD-OCT thickness (µm) 253.62±20.9 260.5±18.7 0.48 256.44±21.6 0.69
Notes: Data presented as mean±sD. independent t-test. *P,0.05 was considered significant.
Abbreviations: BCVa, best-corrected visual acuity; CXl, corneal collagen cross-linking; sD-OCT, spectral domain optical coherence tomography.
Table 2 Changes in BCVa (logMar), CMT (µm), and the five rings of latency as per the mfERG (ms) 7 days after CXL relative to 
pretreatment values
LogMAR BCVA CMT OCT (µm) Latency ring 1 Latency ring 2 Latency ring 3 Latency ring 4 Latency ring 5
1 -0.3 +13 -0.1 +0.6 +0.6 +0.4 -0.3
2 -0.5 +15 +2.8 +1.9 +2.1 +3.6 +1.8
3 -0.4 +13 +1.9 0 +5.6 +4.4 +0.9
4 +0.1 +5 -0.3 +0.6 +0.2 +1.9 0
5 0 +3 -0.7 -0.9 -1.9 0 0
6 0 +5 0 +0.3 -0.1 +1.8 +0.3
7 +0.2 +10 +0.3 -0.2 0 0 0
8 0 +2 +1.6 +0.8 +0.7 +1.9 +0.9
9 -0.1 +11 +1.9 -0.2 +0.6 +1.2 +0.5
10 0 +2 +1.9 +0.5 0 +0.9 +0.8
11 -0.1 +8 -1.5 0 +0.9 +3.0 0
12 +0.2 +6 -1.9 -0.9 -0.3 0 0
13 0 +4 -1.8 -1.8 -0.9 +0.9 -1.0
14 -0.3 +12 -0.7 +0.9 -1.0 +1.0 0
15 -0.2 +11 -0.7 -1.8 -2.3 +0.9 -0.9
16 0 -2 -0.6 -1.9 -0.9 -2.8 -1.9
17 0 -1 -0.9 -0.9 -2.5 0 0
Average -0.08 +6.88 +0.14 -0.17 +0.04 +1.30 +0.06
Notes: Data presented as changes in total values in each eye. Bold values represent the average result of each column.
Abbreviations: BCVa, best-corrected visual acuity; CMT, central macular thickness; CXl, corneal collagen cross-linking; mferg, multifocal electroretinography; OCT, 
spectral domain optical coherence tomography.
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Table 3 regression analysis of P1 latency (ms) as a dependent 
variable with increase in macular thickness as determined by 
mferg
Mean±SD P-value
P1 latency increase 1.59±0.66 0.027a
Note: alinear regression.
Abbreviation: mferg, multifocal electroretinography.
??
??
????
????
????
????
???
??
?? ??????? ????????
?
Figure 1 P1 latency (ms) of ring 4 region. Data from before CXl and 7 days after 
CXl. Paired t-test.
Notes: *P,0.05. Data presented as mean±sD.
Abbreviation: CXl, corneal collagen cross-linking.
?
?
?
???
???
????
????
????
???
????
????
????
??
?
?
?
? ????????????? ?????????????????????? ?? ??
Figure 2 scatter plot for changes in macular thickness and P1 latency.
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Figure 3 P1 amplitude (nV/deg2) of rings 1–5.
Notes: Data from before crosslinking (pre-CXl) and from 7 days after crosslinking 
(post-CXl). Paired t-test. Data presented as mean±sD.
Abbreviation: CXl, corneal collagen cross-linking.
after CXL (Figure 3; Table 4). Mean amplitudes in each ring 
(pre-CXL±SD, post-CXL±SD, P-value) were as follows: ring 
1 (88.38±24.65, 56.60±11.51, 0.0014), ring 2 (45.07±7.14, 
35.72±7.20, 0.0029), ring 3 (29.39±3.65, 25.15±3.50, 
0.0037), ring 4 (19.55±4.16, 15.99±3.09, 0.0014), and ring 
5 (13.48±2.10, 11.37±2.19, 0.0012).
Discussion
Corneal collagen CXL is the only treatment that affects the 
progression of keratoconus and has been found to be effective 
in the stabilization of moderate corneal ectasia, in decreasing 
maximum keratometry, and in improving BCVA.2,6,9,10 In an 
attempt to strengthen the corneal stroma, the eye is exposed 
to a direct source of UVA light, a process which creates ribo-
flavin–UVA-induced crosslinks on the cornea. It is unknown 
whether the UVA light to which the patient is exposed during 
the procedure can pass through ocular structures and cause 
phototoxicity damage to the retina.
It is known, however, that UVA and other light wave-
lengths can produce phototoxic maculopathy,24 a fact which 
raises concern of retinal damage from exposure to UVA light 
during the CXL procedure. Though in vitro studies have 
shown that the shielding effect of riboflavin limits radiant 
transmission on inner ocular structures, few in vivo studies 
have been performed to assess the morphological changes to 
the retina after UVA–riboflavin CXL, and no studies were 
found in the literature on functional damage to the retinal 
tissue.13,22,23
In this study, 17 eyes were evaluated to determine any 
changes to BCVA, structural changes to the retina (SD-OCT, 
AF), vascular status (FA), and function (electrophysiology 
with mfERG) before and after exposure to UVA during the 
CXL procedure. All patients received slit-lamp evaluations 
before the data were collected to ensure that there were no 
opacities on the ocular structures (corneal edema, scars, or 
abnormal surface integrity) that could represent the underly-
ing cause of any abnormalities.
The results showed a slight decrease in BCVA and near 
vision acuity 7 days after the corneal CXL procedure; acu-
ity, however, was found to have been recovered by day 30. 
SD-OCT imaging of the macula region showed increased 
thickness 7 days after CXL and similarly returned to original 
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levels by day 30. None of the differences between the groups 
was statistically significant.
There were no changes in the fundus of the eye as assessed 
using indirect ophthalmoscopy, biomicroscopy, or retinogra-
phy. No changes or abnormalities in macular vascularity were 
observed in the FA, nor was any retinal pigment epithelium 
damage detected by AF imaging. Moreover, typical signs of 
phototoxicity, such as disruption of the inner segment/outer 
segment junction layer, intraretinal cists, or atrophy of the outer 
nuclear layer, were not detected by SD-OCT imaging.
All patients underwent mfERG, so that changes in 
electrical activity and function of the macular region could 
be assessed. Changes are usually defined as an increase 
in P1 latency and a decrease in P1 amplitude. According 
to the literature, symptoms of light damage to the retina, 
such as peri-central scotoma, metamorphopsia, or slight 
to moderate vision loss after light exposure, are typically 
perceived by patients within hours or days.11 For this reason, 
electrophysiological function of the macula was evaluated 
before and 7 days after CXL. Most patients were found to 
have experienced a significant increase in P1 latency (ms) 
of ring 4 (Figure 1). This change was correlated with an 
increase in central macular thickness (Figure 2; Table 3). 
There is no well-known correlation between visual acuity 
and the loci of mfERG rings; however, based on the location 
of ring 4 (macular periphery), neither a change in BCVA 
nor the perception of symptoms would be expected in these 
cases. Furthermore, because BCVA is usually low among 
keratoconus patients for whom CXL is indicated, any mild 
changes in vision resulting from light damage are unlikely to 
be detected. Therefore, changes to the anatomy or function of 
the eye could represent phototoxicity damage. In this study, 
nine subjects (52.9%) also exhibited a significant decrease 
in P1 amplitudes of rings 1–5 (Figure 3), but these changes 
were not correlated with visual acuity or retinal thickness.
The limitations of the study are the number of patients 
(due to their difficulties in attending many follow-up appoint-
ments) and the lack of an electrophysiology evaluation 
30 days after the procedure to analyze further disturbances 
or recoveries from the changes noticed on day 7.
According to other studies, the retina is protected by the 
absorption capacity of the cornea and crystalline lens during 
CXL treatment.18 Although the procedure involved long-term 
(30 minutes of) exposure to UVA light, this study showed that 
the changes observed using SD-OCT and mfERG are not sim-
ilar in nature or magnitude to other phototoxicity conditions 
described previously. This difference could be explained 
by the protective features of the anterior segment25,26 and 
the low UVA light intensity of the procedure relative to the 
intensity associated with typical phototoxicity conditions. 
The SD-OCT findings also reflected an increase in central 
macular thickness, which is the opposite of the typical thin-
ning seen in outer retinal abnormalities. The hypothesis here 
is that this increase in macular thickness could be explained 
by a mild and self-limiting inflammatory reaction to the pro-
cedure and to UV light exposure. This reaction was evident 
7 days after the procedure, but the patients were found to 
have recovered in the evaluations performed 30 days after 
CXL. Further studies are needed to prove or disprove this 
hypothesis. Even so, despite the lack of major differences 
between the groups in terms of BCVA, near vision acuity, and 
SD-OCT thickness, the slight changes seen during mfERG 
could raise concerns over subclinical macular disturbance 
after UVA light exposure during CXL. Given the results of a 
previous study, which showed the standard mfERG is largely 
shaped by on- and off-bipolar cell activity with more limited 
contributions from the photoreceptors and inner retinal (eg, 
amacrine and ganglion) cells,27 the hypothesis resulting from 
the current study is that this atypical presentation of photo-
toxicity would not produce consistent changes to BCVA, 
major visual symptoms, or structural changes that would be 
evident in SD-OCT imaging.
In addition, this is the first study found in the literature 
in which the anatomy, vascularity, and electrophysiology of 
Table 4 Changes in amplitudes of rings 1–5 as per the mferg 
(nV/deg2) 7 days after CXl relative to pretreatment values
Patients Ring 1 Ring 2 Ring 3 Ring 4 Ring 5
1 -17.63 -0.97 -8.74 -5.07 -1.59
2 -39.14 -3.0 -2.61 -4.35 -1.8
3 -5.1 -11.33 -2.88 -3.5 +1.99
4 -60.76 -11.31 -4.89 -7.8 -2.14
5 -49.15 -16.62 -0.47 -0.6 -4.76
6 -45.45 -5.86 -4.73 -3.19 -1.15
7 -42.75 -2.99 +4.3 -4.82 -1.36
8 +32.71 -4.06 +4.55 -4.02 +1.98
9 -16.01 -13.32 +0.06 -1.29 -0.59
10 +29.5 +3.3 +1.69 +3.32 +1.21
11 +15.49 +7.43 -5.08 +0.63 -0.30
12 +7.04 +5.42 -8.72 +5.47 -3.63
13 -11.61 -1.06 -2.43 -3.02 -2.0
14 +28.23 +2.11 -2.66 -1.68 +0.22
15 +3.46 +11.61 +7.06 +4.34 +3.89
16 +24.08 +6.44 +5.64 +4.06 +2.72
17 +29.27 +8.32 -10.03 -7.22 +0.61
average -7.34 -1.40 -1.76 -1.69 -0.39
Note: Data presented as changes in total values in each eye.
Abbreviations: CXl, corneal collagen cross-linking; mferg, multifocal electrore-
tinography.
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Macular phototoxicity after corneal cross-linking
the macula have been analyzed after exposure to UVA light 
from the corneal cross-linking procedure. Larger studies 
with long-term data are needed to further address possible 
phototoxicity of the retina and the safety of corneal cross-
linking for keratoconus patients.
Conclusion
Continuous UVA light exposure during CXL therapy raises 
concerns over potential phototoxicity damage to the retina. 
This study is the first to analyze potential vascular, struc-
tural, and functional changes to the macula in patients with 
keratoconus who have been exposed to UVA light during 
cross-linking therapy. Most of the patients studied herein 
experienced slight changes in central macular thickness (as 
per SD-OCT) and in mfERG parameters, despite the absence 
of typical phototoxicity-related alterations seen in other 
conditions resulting from UV light exposure damage, lack of 
vascular abnormalities as determined by FA/AF imaging, and 
lack of significant changes in BCVA or near visual acuity and 
no report of symptoms. The changes seen could, therefore, be 
categorized as an early and mild subclinical effect on macular 
function after the corneal cross-linking procedure.
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